Scholarlink

Purpose <p>The present study analyzed the clinical efficacy of the herbal medicine “Eppikajyutsuto” (TJ-28) for isolated lymphatic malformation (LM).</p> Methods <p>LM patients treated with TJ-28 monotherapy were retrospectively reviewed using medical records at three pediatric surgery departments from 2009 to 2023. All patients underwent ultrasound or/and magnetic resonance imaging before and after treatment. The isolated LM lesions were classified as macrocystic, microcystic, and mixed cystic according to the International Society for the Study of Vascular Anomalies classification. The LM volume index (LVI) was defined as the longitudinal length (mm) x width (mm) x depth (mm). The degree of reduction ratio (LVI ratio) was defined as the post-administration LVI divided by the pre-administration LVI.</p> Results <p>Thirty-three cases (15 males, 18 females) of LM treated with TJ-28 were enrolled. Data are presented as median (range). The median age started treatment was 20 (0, 112) months. The median treatment duration was 12 (1–81) months. Of 28 patients, LVI ratio was calculated. Eighteen cases had macrocystic LM, 2 cases had microcystic LM and 8 cases had mixed macro–microcystic LM. There were significant differences between the pre-administration and post-administration LVI 32118 [1425, 1125000] mm<sup>3</sup> vs 5087 [0, 50000] mm<sup>3</sup>, <i>p</i> &lt; 0.001). Classified ISSVA: there were significant differences between the pre-administration and post-administration LVI of macrocystic (<i>n</i> = 18) (33,646 [3080, 1125000] mm<sup>3</sup> vs 4937.5 [0, 50000] mm<sup>3</sup>, <i>p</i> &lt; 0.001) and mixed macro–microcystic LM cases (<i>n</i> = 8) (37,952 [1425, 124488] mm<sup>3</sup> vs 5134 [24, 41040] mm<sup>3</sup>, <i>p</i> = 0.0078). For microcystic LM cases (n = 2), there were no significant differences between the pre-administration and post-administration LVI (17,420 [5600, 29240] mm<sup>3</sup> vs 30,180.5 [4550, 55811] mm<sup>3</sup>, <i>p</i> = 0.500). The median LVI ratio was 0.20 (0–1.91). The median LVI ratio of macrocystic LM was 0.21 (0–1.05) and the median LAI ratio of mixed macro–microcystic LM was 0.19 (0–1.01). Microcystic LM cases did not improve.</p> Conclusions <p>This study demonstrates the beneficial effects of TJ-28 for macrocystic LM and mixed macro–microcystic LM.</p> Level of evidence <p>A prognosis study of level IV.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Treatment of isolated lymphatic malformation with the herbal medicine “Eppikajyutsuto”: a retrospective multicenter study

  • 期刊论文

  • 发表日期：

    2025年8月19日

查看全文
  • Naoki Hashizume,
  • Takafumi Kawano,
  • Koshiro Sugita,
  • Motofumi Torikai,
  • Shun Onishi,
  • Daisuke Masui,
  • Saki Sakamoto,
  • Hideaki Egami,
  • Satoshi Ieiri,
  • Tatsuru Kaji

摘要

Purpose

The present study analyzed the clinical efficacy of the herbal medicine “Eppikajyutsuto” (TJ-28) for isolated lymphatic malformation (LM).

Methods

LM patients treated with TJ-28 monotherapy were retrospectively reviewed using medical records at three pediatric surgery departments from 2009 to 2023. All patients underwent ultrasound or/and magnetic resonance imaging before and after treatment. The isolated LM lesions were classified as macrocystic, microcystic, and mixed cystic according to the International Society for the Study of Vascular Anomalies classification. The LM volume index (LVI) was defined as the longitudinal length (mm) x width (mm) x depth (mm). The degree of reduction ratio (LVI ratio) was defined as the post-administration LVI divided by the pre-administration LVI.

Results

Thirty-three cases (15 males, 18 females) of LM treated with TJ-28 were enrolled. Data are presented as median (range). The median age started treatment was 20 (0, 112) months. The median treatment duration was 12 (1–81) months. Of 28 patients, LVI ratio was calculated. Eighteen cases had macrocystic LM, 2 cases had microcystic LM and 8 cases had mixed macro–microcystic LM. There were significant differences between the pre-administration and post-administration LVI 32118 [1425, 1125000] mm3 vs 5087 [0, 50000] mm3, p < 0.001). Classified ISSVA: there were significant differences between the pre-administration and post-administration LVI of macrocystic (n = 18) (33,646 [3080, 1125000] mm3 vs 4937.5 [0, 50000] mm3, p < 0.001) and mixed macro–microcystic LM cases (n = 8) (37,952 [1425, 124488] mm3 vs 5134 [24, 41040] mm3, p = 0.0078). For microcystic LM cases (n = 2), there were no significant differences between the pre-administration and post-administration LVI (17,420 [5600, 29240] mm3 vs 30,180.5 [4550, 55811] mm3, p = 0.500). The median LVI ratio was 0.20 (0–1.91). The median LVI ratio of macrocystic LM was 0.21 (0–1.05) and the median LAI ratio of mixed macro–microcystic LM was 0.19 (0–1.01). Microcystic LM cases did not improve.

Conclusions

This study demonstrates the beneficial effects of TJ-28 for macrocystic LM and mixed macro–microcystic LM.

Level of evidence

A prognosis study of level IV.